Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
ACA, affiliation, alnuctamab, Amelyn, amplify, Arzneimittel, aspire, Avencell, AZ, barred, BeiGene, belonging, bhatt, Biden, Biohaven, blockbuster, blocking, bold, boldly, brain, BridgeBio, capsule, ceiling, cendakimab, Chamber, checkpoint, chemoimmunotherapy, Claudin, clawback, CLL, Codification, cohesive, colorectal, commerce, compassionate, conflict, cornerstone, cut, dataset, decree, deepak, Denmark, deserve, dialogue, discharge, dispense, disproportionately, Dutch, ecteribulin, elevate, Eli, emotional, energized, energizing, EoE, eosinophilic, epidemic, equitable, ESG, ethical, Eureka, Exscientia, factual, farletuzumab, faster, Finland, Genentech, grown, gym, Handa, hardship, HK, hoc, IIB, IIC, Imfinzi, Imjudo, imminent, implicate, inactive, IRA, judge, LaNova, LianBio, longstanding, LOTTE, LP, LSA, Macau, MDRP, membership, Memorial, mental, mindset, motivated, mounted, MPH, MSI, MSS, multicenter, Nanocopoeia, neighboring, neurodegenerative, NKC, Nonrefundable, Norway, NTD, NTRK, obsolete, oncogenic, opdualag, operationalized, overwhelming, PAISLEY, permission, PFS, phototherapy, Pillar, PKC, planet, platinum, polarized, prepaid, pressing, PSO, pursuit, RADIANCE, ratio, reasserted, reevaluated, render, repotrectinib, repricing, resiliency, restrain, role, RS, Russian, saving, sense, serologic, Servier, SHARON, Sherman, sideroblast, skill, SLE, Sotyktu, startup, statutorily, Swedish, Syracuse, tackle, Takeda, TCER, Thailand, Thirteenth, threat, thyroid, tour, transfusion, turn, Turning, unanimously, underway, unlock, upcoming, VAT, vendor, wage, Xspray
Removed:
academic, Acceleron, accept, adjudication, advisory, aided, Anagni, annuity, apremilast, Asia, asserted, ASU, Athene, Azar, Bancroft, behavior, bench, bill, biology, biopharma, blend, burden, cabozantinib, call, capitalization, capped, Catalent, CELMoD, closely, collar, collected, colon, Columbia, converted, Cormorant, CPPIB, credited, declined, deficient, deploying, differentiated, discontinuation, discrete, divest, DLBCL, donut, Dr, DRL, element, encounter, Erbitux, ERISA, Eugia, exchanged, finalized, focusing, forfeiture, forma, FTC, gemoab, genetic, halted, hampered, heightened, hepatocellular, hole, HR, HRSA, idiopathic, ImClone, immunologic, indolent, infusing, ingested, interrupted, intolerant, invalidate, IPF, irrevocably, Jr, KGaA, leaner, lengthen, leveraged, LRR, lump, Luxembourg, Lynch, medically, mismatch, modulator, Mylan, NACHT, Notwithstanding, optimistic, originally, overcome, penalty, Pennsylvania, perception, pill, placement, premium, principle, pro, promise, Prostaglandin, protocol, purport, PYD, randomized, rationalization, Reddy, reengineer, reengineered, repair, replaced, rest, restoring, retained, RRMM, RSU, salesforce, SANTIAGO, SAS, SCCHN, Schmukler, SCLC, shorten, sorafenib, spent, standstill, strike, strongly, suffered, tendered, tradeable, tranche, transformation, transformed, TRICARE, unaudited, unconstitutional, unexercised, unfavorable, unwinding, upper, UPSA, USA, vivo, waiver, weighted, wholly, window, XIa, Zofingen
Filing tables
Filing exhibits
- 10-K Annual report
- 4 Description of Bristol-myers Squibb Companys Securities
- 10 Msu Agreement Under the 2021 Stock Award and Incentive Plan
- 10 Psu Award Agreement Under the 2021 Stock Award and Incentive Plan
- 10 Rsu Agreement with 5-YEAR Vesting Under the 2021 Stock Award and Incentive Plan
- 10 Rsu Agreement with 4-YEAR Vesting Under the 2021 Stock Award and Incentive Plan
- 10 Rsu Agreement with 3-YEAR Vesting Under the 2021 Stock Award and Incentive Plan
- 10 Rsu Agreement with 2-YEAR Cliff Vesting Under the 2021 Stock Award and Incentive
- 10 Rsu Agreement with 1-YEAR Cliff Vesting Under the 2021 Stock Award and Incentive
- 21 EX-21
- 23 EX-23
- 31 EX-31.A
- 31 EX-31.B
- 32 EX-32.A
- 32 EX-32.B
- Download Excel data file
- View Excel data file
Related press release
Associated BMY transcripts
BMY similar filings
Filing view
External links
EXHIBIT 32b
Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as
Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U. S. C. Section 1350, I, David V. Elkins, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the Report), as filed with the Securities and Exchange Commission on February 14, 2023, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Bristol-Myers Squibb Company.
/s/ David V. Elkins | ||
David V. Elkins Chief Financial Officer |
February 14, 2023
This written statement is being furnished to the Securities and Exchange Commission as an exhibit to the Report. A signed original of this written statement required by Section 906 has been provided to Bristol-Myers Squibb Company and will be retained by Bristol-Myers Squibb Company and furnished to the Securities and Exchange Commission or its staff upon request.